Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
J Clin Pathol. 2022 Aug;75(8):506-513. doi: 10.1136/jclinpath-2022-208186.
Cancer datasets recommend standardised reporting of histopathological data items with elements categorised as either core (required) or non-core (recommended), irrespective of the clinical scenario. However, the clinical significance of a data item in an individual case would depend on the clinicopathological setting as well as local management guidelines. A data item that is critical for patient management in one clinical scenario may be largely irrelevant in another patient. Pathologists must understand how their data are used in clinical practice so that they can focus their limited resources appropriately. We briefly review the use of histopathological data in the management of urological cancers, highlighting scenarios where a data item may be of limited clinical utility.
癌症数据集建议对组织病理学数据项进行标准化报告,这些数据项的元素分为核心(必需)或非核心(推荐),无论临床情况如何。然而,在个别病例中,数据项的临床意义将取决于临床病理环境以及当地管理指南。在一种临床情况下对患者管理至关重要的数据项,在另一种情况下可能基本不相关。病理学家必须了解他们的数据在临床实践中的使用方式,以便能够适当地集中他们有限的资源。我们简要回顾了组织病理学数据在泌尿系统癌症管理中的应用,重点介绍了数据项可能具有有限临床效用的情况。